Company / R&D per Share
Acadia Pharmaceuticals R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.97
FY2025
5-year range
$1.50 / $2.25
FY2021-FY2025
Trend
+7.1%
vs FY2024
Sector context
#105 of 208
Health Care
What the data says
At $1.97, Acadia Pharmaceuticals's r&d per share ranks #105 of 208 in the Health Care sector. R&D per Share returned to growth in FY2025 after 2 years of decline, reaching $1.97.
Based on SEC 10-K filings.
1.97 in FY2025 with a 5-year CAGR of -0.8%.
Declined from $2.17 to $1.97 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -4.2%
- 5-Year CAGR
- -0.8%
- 10-Year CAGR
- -
Sector benchmark
#105 of 208 in Health CareTop 50% of 208This company $1.97 Sector average $12.19
▼
-83.8% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 7.1% year-over-year.
- Ranks #105 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.97 | +7.1% |
| FY2024 | $1.84 | -15.1% |
| FY2023 | $2.17 | -3.4% |
| FY2022 | $2.25 | +49.7% |
| FY2021 | $1.50 | -27.0% |
| FY2020 | $2.06 | +23.0% |
| FY2019 | $1.67 | +11.1% |
| FY2018 | $1.50 | +22.4% |
| FY2017 | $1.23 | +26.2% |
| FY2016 | $0.97 | +31.9% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026